Bio-Rad Laboratories, Inc.
BIO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,566,500 | $2,671,262 | $2,802,249 | $2,922,545 |
| % Growth | -3.9% | -4.7% | -4.1% | – |
| Cost of Goods Sold | $1,187,600 | $1,244,316 | $1,234,919 | $1,284,449 |
| Gross Profit | $1,378,900 | $1,426,946 | $1,567,330 | $1,638,096 |
| % Margin | 53.7% | 53.4% | 55.9% | 56.1% |
| R&D Expenses | $295,900 | $247,427 | $256,889 | $260,638 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $814,000 | $841,700 | $827,825 | $877,122 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,109,900 | $1,089,100 | $1,084,714 | $1,137,760 |
| Operating Income | $269,000 | $337,796 | $482,616 | $500,336 |
| % Margin | 10.5% | 12.6% | 17.2% | 17.1% |
| Other Income/Exp. Net | -$2,611,500 | -$1,187,900 | -$5,186,889 | $4,948,719 |
| Pre-Tax Income | -$2,342,500 | -$850,104 | -$4,704,273 | $5,449,055 |
| Tax Expense | -$498,300 | -$212,780 | -$1,076,738 | $1,194,798 |
| Net Income | -$1,844,200 | -$637,324 | -$3,627,535 | $4,254,257 |
| % Margin | -71.9% | -23.9% | -129.5% | 145.6% |
| EPS | -65.36 | -21.82 | -121.79 | 142.61 |
| % Growth | -199.5% | 82.1% | -185.4% | – |
| EPS Diluted | -65.36 | -21.82 | -121.79 | 140.83 |
| Weighted Avg Shares Out | 28,214 | 29,209 | 29,785 | 29,831 |
| Weighted Avg Shares Out Dil | 28,214 | 29,209 | 29,785 | 30,208 |
| Supplemental Information | – | – | – | – |
| Interest Income | $82,000 | $100,900 | $58,000 | $18,900 |
| Interest Expense | $48,900 | $49,439 | $38,114 | $1,551 |
| Depreciation & Amortization | $151,600 | $145,900 | $177,200 | $137,600 |
| EBITDA | -$2,142,000 | -$654,800 | -$4,488,959 | $5,588,206 |
| % Margin | -83.5% | -24.5% | -160.2% | 191.2% |